Akebia Therapeutics, Inc.

Ladies and gentlemen, thank you for standing by. And welcome to Akebia's Therapeutics Fourth Quarter of 2020 Financial Results Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you'll need to press star 1 on your telephone. Please be advised that today's conference is being recorded. If you require any further assistance, please press star 0. I would now like to hand the conference over to your speaker today, Kristen Shepard, Senior Vice President of Investor Relations. Thank you. Please go ahead.

Thank you, and welcome to Akebia's fourth quarter and fiscal year 2020 Financial Results and Business Update conference call. Please note that the press release detailing our results for the fourth quarter and fiscal year 2020 was issued earlier this morning and is available on our Investor Relations website. For your convenience, a replay of today's call will also be available on our website shortly after we conclude today's event. Joining me for today's event is John Butler, our Chief Executive Officer, and David Spellman, our Chief Financial Officer. Before we begin, I'd like to remind everyone that this call includes forward-looking statements. Each forward-looking statement contained in this call is subject to risks and uncertainties that could cause actual results to differ materially from those described in these statements. Additional information regarding these factors is described in the forward-looking statements section of the press release we issued earlier today, as well as in the risk factors in management's discussion and analysis sections of our most recent quarterly and annual reports filed with the FCC. The four looking statements on this call speak only of the original date of this call, and except as required by law, we do not undertake any obligation to update or revise any of these statements. With that, I'd now like to introduce our CEO, John Butler. John?

Thank you, Kristen, and thank you all for joining us today. 2020 was a year of focused execution for Akibia. We set out to accomplish a lot in 2020, and we did what we said we would do, advancing Vatadustat, our lead product candidate, and laying the groundwork for a number of catalysts in 2021. More specifically, we achieved key clinical and regulatory milestones, including completing our global Phase III clinical development program for Vatadustat, and completing our pre-NDA meeting with the FDA. We also executed well against our commercial priorities. After securing the first regulatory approval of Vatadustat with our partner, MTPC, earlier in the year, we began supporting the commercialization of Vatadustat in Japan under the trade name Vafseo in Q3. As a company whose purpose is to better the lives of people impacted by kidney disease, I've been saddened to watch the disproportionate impact COVID-19 has had on patients on dialysis. Our team did a tremendous job of helping ensure that these patients who continue to be at the highest risk have access to our therapies despite the pandemic. As a result of these and other efforts, we grew Eurexia revenue over 2019. I'm incredibly proud of our entire team for all their work across 2020. and their continued commitment to both our purpose and our patients. Importantly, we achieved all this and more while keeping true to our goal of maintaining a strong balance sheet. With forward momentum from 2020, we have line of sight to significant milestones this year that we believe will further position Akibia to deliver on our strategy and build long-term value for our shareholders. Our highest priority is submitting our NDA for Vatadustat for the treatment of anemia due to CKD with the FDA. Since completing our pre-NDA meeting in late October, our team has been hard at work putting together a very detailed and comprehensive data package in support of Vatadustat's NDA submission. We remain firmly on track to achieve this milestone by the middle of the second quarter of this year. We also expect to follow this with Vatadustat's MAA submission to the EMA in collaboration with Otsuka this year. As we advance Vatadustat towards commercialization subject to approval, we continue to execute on key commercial, development, and financial priorities across our business. As dialysis is a primary focus, I'll start there. Data from Innovate, our global phase three program that evaluated the efficacy and safety of Vatadustat in patients on dialysis were clear, consistent, and compelling. The data showed that Vatadustat achieved non-inferiority to darbopoietin alpha on both the primary and key secondary hematologic efficacy endpoints, as well as the primary and key secondary safety endpoints that included MACE, expanded MACE, cardiovascular MACE, cardiovascular mortality, and all-cause mortality. Going a little deeper, Our clinical data also demonstrated that Vatadustat maintained EPO within a physiologic range, increased hemoglobin in a predictable and controlled manner, and minimized hemoglobin excursions above that target range. We believe dialysis represents a potential $2 billion market opportunity in the U.S. alone. We're confident that upon approval, we have the potential to address the unmet needs of the over 500,000 adult patients on dialysis in the U.S. and rapidly establish Vatadustat as the new oral standard of care for the treatment of anemia due to CKD. We anticipate that the strength of our data, which is clear and consistent across both prevalent and incident dialysis patients, will play a meaningful role in helping develop treatment protocols within dialysis providers. which are critical to driving adoption in the dialysis market, subject, of course, to regulatory approval. To further strengthen Vatadustat's potential profile for in-center dialysis patients, we're working to demonstrate that Vatadustat can also be dosed three times a week and plan to have that data available at launch, which will allow us to submit an SNDA for this regimen post-approval. Although the significant majority of dialysis patients are cared for in-center, recently several factors, including the COVID-19 pandemic, changing patient preferences, government initiatives, and reimbursement changes are supporting a shift towards home dialysis. We believe that as a convenient, once-daily oral therapeutic, Vatadustat has the potential to offer an important value proposition both to the growing number of home dialysis patients and to dialysis providers looking to better support these patients and grow their home programs. We believe we are well positioned to support a strong Vatadustat launch in dialysis in the U.S. upon approval. Our go-to-market strategy includes leveraging our existing nephrology-focused commercial organization with our partner Otsuka sharing in the launch costs and responsibilities. As well, we have an exclusive distribution relationship with V4 Pharma that positions Vatadustat for potential rapid adoption in up to 60% of the U.S. dialysis market. Adding to this is a unique reimbursement model in the U.S. dialysis market with TDAPA, an add-on payment to the bundle that's intended to encourage adoption of innovative therapies by clinicians and dialysis providers. To maximize our market potential and ensure commercial readiness upon U.S. approval, we're executing across many different work streams within medical affairs, scientific communications, disease state education, patient services, and manufacturing. We also recently added Leanne Zumwalt to our Board of Directors. Many of you may know Leanne as she spent over 20 years serving in key leadership roles with DaVita, most recently as Group Vice President of Government Affairs before her retirement earlier this year. Leanne's perspective and extensive operating experience with one of the largest dialysis providers in the U.S., will help ensure that our market and commercial strategies are well aligned with the needs of dialysis providers and their patients. We, along with the Executive Steering Committee, who has overseen our Phase III development program, believe it is critical to publish our data. And collectively, we continue to execute on our robust publication plan. To date, this has included the presentation of our Phase III data at ASN, and publication of both our Innovate and Protect Methods papers in peer-reviewed journals during the fourth quarter. Looking ahead, we plan to present additional data at the upcoming NKF spring clinical meetings in April, and we have line of sight to publication of our Innovate program in a prestigious peer-reviewed publication expected in the near term. Protect has been submitted earlier this year for publication as well. Again, there is a significant unmet need among patients with anemia due to CKD, and we see a promising opportunity in Vatadustat to advance the care of patients on dialysis. Turning to non-dialysis, as we discussed last quarter, we plan to submit data from PROTECT together with additional analyses and pursue a broad label for adult patients not on dialysis as part of our Vatadustat NDA submission. However, as PROTECT missed the primary MACE endpoint, we are remaining cautious on potential approval in non-dialysis. Now, in compiling the NDA, we've been able to take a deeper dive into the data to better understand PROTECT's MACE result. The cardiovascular outcomes reported in PROTECT contrast with those reported in the Innovate program, as well as with the safety data from other clinical and preclinical studies of Atadustat in both dialysis and non-dialysis adult patients. Additional in-depth analyses conducted by our team continue to demonstrate that the greater number of MACE events observed among Vatadustat patients not on dialysis, as compared with those on Darbopo and Alpha in the PROTECT program, was primarily related to an excess of non-cardiovascular deaths and deaths of unknown cause in regions outside of the United States where significant differences in treatment patterns for patients not on dialysis were observed. As we've previously discussed, we believe these and other analyses inform the cardiovascular safety profile of Vatadustat in U.S. patients not on dialysis. We continue to believe that pursuing approval in non-dialysis is the right thing to do for patients, and we look forward to working with the FDA in their review. In addition, I want to share that as part of our NDA work, we undertook a review of hepatic safety across the Vatadustat clinical programs. which includes data from over 8,000 patients across 36 completed Phase I, II, and III clinical studies conducted by Akibia and our partner, MTPC. The review of hepatic safety included a blinded assessment of all hepatic events in the studies by a panel of hepatic experts and analysis by an independent hepatic expert and our team. I'm very pleased to report that, based on this review, we concluded that the data across the clinical program showed that the hepatic safety profiles of Vatadustat and Darbopoietin-alpha in injectable ESA and the current standard of care appear to be similar, and that there were no HISE law events identified across the entire Vatadustat clinical development program. More specifically, we concluded that a 2014 case previously reported by us as meeting the biochemical criteria for Heise law, while complicated, was in fact not a case of Heise law. Our conclusion on this case will be reflected in our NDA for Vatadustat. We wanted to share this report finding as we believe it reinforces what we expect will be a high-quality NDA submission for Vatadustat. As well, this finding reinforces our confidence around the long-term strategic vision for Vatadustat. An important aspect of this strategy is focused on innovation. So let me shift a little bit and talk about our future development plans. Innovation is a core capability at Akebia that we have built over the past decade with robust research and clinical development resources. This engine has yielded significant scientific advancements, including Vatadustat, which is based on Nobel Prize winning science. While the near-term and largest commercial opportunity for Vatadustat is within anemia due to CKD, we believe there is the potential for additional opportunities for Vatadustat. We're encouraged that the current study evaluating the use of Vatadustat as a potential therapy to prevent and lessen the severity of acute respiratory distress syndrome, or ARDS, in adult patients who've been hospitalized due to COVID-19 is progressing well. As a reminder, This is a clinical investigator-sponsored study led by UT Health that we provided supportive funds for last year. UT Health has shared that over 120 patients are enrolled and recently announced that they have been awarded $5.1 million in funding from the US Department of Defense to expand this clinical trial at their facilities. If the results of this study are positive, we believe this COVID-related clinical experience could offer possibilities not only to move forward and help COVID patients, but also to explore Vatadustat for a large and enduring opportunity as a treatment for ARDS beyond COVID. After being relatively quiet in 2020, we look to share more information on potential development opportunities for Vatadustat later this year and where possible, updates from UT Health. To sum up, as we transition to 2021, we plan to continue executing to prepare for the expected commercialization of Vatadustat while investing in potential opportunities to help position Akibia for the long term. We're pleased to be doing all this from a place of financial strength, with a cash runway that extends beyond the expected U.S. launch of Vatadustat, assuming timely regulatory approval and the receipt of associated regulatory milestones. And as Dave will discuss, we remain committed to both maintaining a strong balance sheet and improving our cost structure moving forward. In furtherance of these objectives, we recently announced a $60 million transaction with healthcare royalty partners to monetize our Vafseo royalties and sales milestones under our collaboration agreement with MTPC. While Dave will provide more details shortly, we believe this transaction is strong validation of the value that Vafseo can bring to patients in Japan. As well, we believe it underscores our commitment to preserving both our strategic and financial flexibility while investing for the successful launch of Adadustat upon approval. As we head into the next chapter of Akebia, there's a lot of important work ahead of us in 2021. We remain confident that our hard work in 2020 has laid the foundation for the year ahead and the journey that we're on for the longer term. We're excited about the future, and together with our collaborator, Otsuka, we look forward to bringing Vatadustat for the treatment of anemia due to CKD to patients globally upon approval. I'll now turn the call over to Dave, who will review our financial results. Dave?

Thank you, John, and good morning, everyone. As John discussed, we met key goals in 2020, including the headline, completing our Phase III development program for Vatadustat, We also demonstrated the resiliency of our organization and business in response to challenges across the year. Despite these challenges, I'm pleased that we were able to continue supporting our patients and customers and accomplish all that we did while keeping with our objective to maintain a strong balance sheet. This progress underscores our focus on execution and our commitment to our patients. Before reviewing our 2020 financial results, I'd like to provide some detail around our recent $60 million non-dilutive transaction with healthcare royalty partners to monetize our Vafseo royalties and associated sales milestones under our collaboration agreement with MGPC, which for clarity is not included in our 2020 results. Under the terms of the agreement with HCRP, Akibia receives an upfront cash payment of $45 million and is eligible to receive an additional $15 million if certain sales milestones are achieved. In exchange, each CRP has the right to receive VASEO royalties and sales milestones due to us under our collaboration agreement, subject to an annual cap of $13 million and an aggregate cap of $150 million. After the annual cap is met in any given calendar year, Akibia will recognize 85% of VASEO royalties and sales milestones from MTPC for that year. After the aggregate cap is met, Akibia will recognize 100% of the VASEO royalties and sales milestones until the revenue stream ends under the terms of the company's collaboration agreement with MTPC. The transaction does not include potential future regulatory milestones to be paid by MTPC. We're very pleased with this transaction. As a reminder, the third quarter marked the first commercial availability of Vafseo in Japan. Since launching in late August, we recorded approximately $400,000 in royalty revenue related to the sale of Vafseo in Japan by Mitsubishi Tanabe. Now turning to our financial results, starting with revenue. Total revenue was $56.7 million for the fourth quarter of 2020, compared to $69.6 million for the fourth quarter of 2019, and $295.3 million for the full year 2020, compared to $335 million for the full year of 2019. The decline in both periods was driven by lower collaboration revenue consistent with the company successfully completing our Global Phase III Clinical Development Program for Vata-Dustat, which included the Innovate and Protect studies. As you know, 80% of our Phase III VAT adduce debt development costs are pre-funded by our collaborator, OTSUCA, and these corresponding payments are recorded as collaboration revenue. So, as these costs decline, so will the corresponding payments. Separately, I'll note that subject to the terms of our collaboration agreement with OTSUCA, Akebia has the potential to receive both regulatory and commercial milestone payments from OTSUCA upon the approval and commercialization of Vatadustat in both the U.S. and Europe. Collaboration revenue was $22.1 million for the fourth quarter of 2020 compared to $40.6 million for the fourth quarter of 2019 and $166.4 million for the full year 2020 compared with $223.9 million for the full year 2019. As I just mentioned, the change in both periods is due to the timing in which VAT-adduced debt development expenses are incurred, and the associated revenue is recognized on a percentage of complete basis. Also, this includes approximately $400,000 in royalties from MTPC received in 2020. In terms of Akiva's commercial performance, Net product revenue for Arixia was $34.6 million for the fourth quarter of 2020, compared with $28.9 million for the fourth quarter of 2019, an increase of 20%. And $128.9 million for the full year 2020, compared to $111.1 million for the full year of 2019, an increase of 16%. We are very proud that our team continued to execute across 2020, getting our therapies to those in need, While we did not experience significant impact from COVID-19 on our revenues during the first nine months of 2020, we believe there was an impact on our revenue growth in Q4, primarily as the kidney patient populations that we serve continue to experience both higher hospitalization and mortality rates due to COVID-19. As COVID-19 continues to adversely and disproportionately impact our patient population, we expect that COVID-19 will have a negative impact on future revenue growth. Cost of goods sold was $63.2 million for the fourth quarter of 2020 compared to $38.1 million for the fourth quarter of 2019, excluding non-cash purchase accounting adjustments as a result of the merger with Carex. The increase in the fourth quarter of 2020 was primarily driven by a $14.8 million non-cash charge related to excess purchase commitments. Cost of goods sold was $295.9 million for the full year 2020, compared with $145.3 million for the full year 2019. Cost of goods sold for 2020 includes a $115.5 million non-cash charge related to the impairment of the Arixia intangible asset in the second quarter of 2020, a $25.1 million non-cash charge related to excess purchase commitments, and a $20.1 million non-cash charge for inventory write-downs, largely related to a previously disclosed manufacturing quality issue related to Orixia. We expect COGS to normalize in the second half of 2021 as we continue to focus on quality and work through remaining non-cash purchase accounting adjustments associated with inventory. Research and development expenses were $37.6 million for the fourth quarter of 2020 compared to $80.4 million for the fourth quarter of 2019 and $218.5 million for the full year 2020 compared to $323 million for the full year 2019. Again, the decline in both periods was driven primarily by a decrease in the cost consistent with the company completing the Innovate and Protect studies. We continue to expect that R&D expenses will remain significant as we continue to support ongoing planned clinical work as well as the cost of our supply chain and inventory build ahead of the expected approval of Vatadustat. Selling, general, and administrative expenses were $40.3 million for the fourth quarter of 2020 compared to $44.9 million for the fourth quarter of 2019. and $153.9 million for the full year of 2020, compared to $149.5 million for the full year of 2019. For 2021, we expect that SG&A expenses will increase modestly from 2020 as we invest in pre-commercial activities for Vatadustat and continue to support Orexia. For our bottom line, the company reported a net loss of $87 million for the fourth quarter of 2020, compared to $94.5 million for the fourth quarter of 2019 and $383.5 million for the full year of 2020, compared to $279.7 million for the full year 2019. The increase in net loss for the full year 2020 was primarily due to lower collaboration revenue and higher COGS, partially offset by lower operating expenses. Turning to our capital position, Cash, cash equivalents, and available for sale securities were $268.7 million at December 31, 2020. This balance includes the remaining $20 million available under our loan agreement with Pharmacon that we drew down in the fourth quarter, as well as $10.6 million in proceeds from the sales under our ATM in the fourth quarter. Additionally, we added approximately $15.9 million in proceeds from ATM sales subsequent to year-end. As COVID-19 continues to adversely and disproportionately impact our patient population with higher hospitalization and mortality rates, we expect this will have a negative impact on Arixia revenue growth. While we are unable to fully quantify the impact of the COVID-19 pandemic on future revenues and revenue growth, we continue to work to position the company to navigate these challenges. As such, our financial priorities remain focused on improving our cost structure and maintaining a strong balance sheet as evidenced by our recent royalty transaction with HCRP that I mentioned earlier. From a tactical perspective, in addition to being disciplined on the investments we make, we remain focused on quality, driving efficiencies and improvements in manufacturing and supply chain, managing costs and driving operating leverage from our existing commercial resources, as we move toward an expected Vatadustat launch in the U.S. subject to approval. To wrap up, we expect our cash resources to fund our current operating plan beyond the expected U.S. launch of Vatadustat, assuming timely regulatory approval and the receipt of associated regulatory milestones. With that, we'll open up the line for questions. Operator?

Thank you. As a reminder, to ask a question, you'll need to press star 1 on your telephone. To withdraw your question, please press the pound key. Please stand by while we compile the Q&A roster. Our first question comes from Chris Raymond with Piper Sandler. Your line is open.

Hey, thanks. Just a couple of questions here. Maybe first on, you know, your color on the impact to Eryxia or the renal business, maybe writ large from COVID. So it... First, John, renal, of course, is notoriously promotion sensitive as a specialty group. Is there also maybe any impact you're seeing from the fact that your reps can't access clinics like they used to? And then maybe, I know you guys talk sort of in generalities about how this COVID impact might spill over into 2021, but maybe can you give some color on how to think about this? I guess on one hand, case rates across the U.S. have been sort of coming down, but the first part of Q1 was still pretty high. So maybe is there any more color you can give on how you think that would play out this year? Thanks.

Sure, Chris. You know, certainly it's an interesting question. I mean, it's hard to kind of parse it out. You know, I've been pretty impressed by the kinds of access our reps have been able to get. It's really different parts of the country to parts of the country. Some are back in the field. Some are still working on Zoom, but quite effective when they get there. I mean, if you look at the fourth quarter, for instance, I mean, the product grew in but just not as much as we had expected. And when you look at the overall prescriptions in the phosphate binder category, the overall prescriptions were dropping. Now, the size of the prescription is a little higher, but it says that there's an impact from COVID, and it's not just an access. Particularly when you listen to Fresenius, Davida, on their calls earlier this quarter, you know, they're talking about a clear impact to their patients, and, you know, there's data, I can't remember the source, that the mortality rate among dialysis patients is 20%, way higher than the rest of the population. Exactly how that plays out is very hard, obviously, to say. First quarter always is a soft quarter for us because we have the prior ops that we have to go through. The team knows how to do that, but How the excess mortality and hospitalization also plays into that is much harder to say. We've been pushing, in my KCP role, we talked about prioritizing dialysis patients for vaccine. Think that's happening in different states, so exactly how long this plays out, but if we've lost patients, we've lost patients, and I do think that's going to have an impact, exactly how much to be determined.

Okay, maybe, thanks, and maybe also a follow-up, just on that, so I think you're guiding now, I think, a little bit more color on timing, so mid this year. Maybe just on use of that PRV, is there a point when you'll be able to, you know, give some indication as to whether you can actually use that?

So just to clarify, it's mid-second quarter is the guidance, which is a little earlier than mid-year. Yeah, sorry. Yep, no problem. And, you know, we still have the potential to access the PRV. and that's a decision we would make with V4 and with Otsuka. So, you know, we still have that, but beyond that, not ready to comment.

We would issue a press release when we submit and have an occasion at that point in time.

Yeah. Thanks, Kristen. Yeah, we will issue a press release, and then you'll know. Okay. Thanks, you guys.

Thank you. And our next question comes from Defe Yang with Mizuho. Your line is open. Would you check your mute button? I'll go to the next line. Yifei Yang, your line is open. Yes, I'm here. Can you hear me?

Yes.

Hi, Yifei.

Hi, good morning, and thanks for taking my question. Just a couple quick ones. With regards to the Heist Law case, you were talking about eventually were able to determine it was not a high-slot case. Would you give us a little bit more color on what led to that decision? And then secondarily, with regards to the once-daily dosing versus the three-times-weekly dosing, and how do you think it will be utilized in the field?

Sure. So first on the Heisler case, this was a complicated case. I mean, that I can't stress enough. I mean, it was a patient with very elevated liver enzymes levels, but never was hospitalized, never symptomatic. But we said at the time when we reported it that we were always looking at our data. Now, post-Protect and Innovate, we're looking at 8,000 patients, and we were able to have an outside expert panel do a blinded assessment and look at all of the data with that lens and the lens of 8,000 more. And beyond just the Heise Law case, the fact that Vatadustat versus Darbut-Poetin, a product that's never been shown to have any kind of liver impact, we determined that there's really no difference between those. So that's a very important finding. And similarly... with the single Heisman Law case. Complicated case, continued to look at it. Looking at that as part of this blinded review, we've made this determination. And at the time, I mentioned when we first reported it that this is how we had reported it to the FDA. Now, I also mentioned in our NDA, we're saying that this wasn't a Heisman Law case, and we wanted to make sure that we reported that to you as well. And then the second question was on three times weekly versus daily. And the three times weekly dosing is important for the in-center dialysis. We have those studies ongoing. We expect to have data at launch, and that will allow us to submit a supplemental NDA quickly. But one of the interesting things, kind of things that's happening in the dialysis treatment is that there's a really significant push towards home dialysis. And, you know, whether that's the COVID impact, which is clear, there's some reimbursement, schemes that are pushing people to expand that program, and the dialysis providers want to expand those programs. And that's less than 20% of the market today, but the fastest-growing part of the market. And we think that having the once-a-day option for those patients is ideal, and we think that will be something that people will want to adopt quickly.

Thank you for taking my questions.

Thanks, D. Faye.

Thank you. Our next question comes from Ed Arcee with H.C. Wainwright. The line is open.

Great. Thanks, everyone. Thanks for taking my question. Just a couple. I just wanted to ask John if you could discuss in a bit more detail your mention of the analysis of PROTECT and how it was found that the excess of deaths were primarily non-cardiovascular and in patients ex-US. If you could just give us a bit more detail around what you found and also, is there any possibility, you know, given... I guess, does that... give you increased confidence of a potential for the approval in non-dialysis?

Ed, thanks for the question. It's an important one. And I think I want to make sure I say up front, again, you know, kind of that we did miss the overall primary safety endpoint, right? And that is, you know, with that, I think we should all be cautious. But, you know, at the end of the day, the question is, you know, what's the cardiovascular safety profile of the product? And, you know, As I mentioned, when you look at that ex-U.S. population, you did see the excess mortality was driven by non-cardiovascular and deaths of unknown cause. And very importantly, when you think about how non-dialysis patients are treated globally, and you look at some of the markets here, they're just very different treatment paradigms for non-dialysis patients around when they start therapy, whether they're offered dialysis or not, et cetera. And there's no smoking gun here, but when you look at the overall picture and then you look at that U.S. data, which we know how patients are treated very consistently there, You know, we think that that demonstrates that the Vatadustat does have an acceptable risk. And I think also when you think about dialysis treatment, dialysis treatment is much more homogeneous across the world. You know, once you start dialysis and look at the Innovate data, it was very consistent globally. We still missed the primary safety endpoint. This will be a review issue, but we think it's the right thing for patients to submit an application for both the dialysis and non-dialysis indications.

Okay, great. That's helpful. Then just one other question you had touched upon earlier with regards to the negative impacts of COVID-19 on future Oryxia growth. I was just curious as to why I think you said that the impacts really weren't felt until the fourth quarter and are expected to continue through at least the foreseeable future into this year. Just curious as to what specifically you think is, was missing in the second and third quarter that led to manageable impacts there?

Thanks. It's a great question, Ed. And I think, you know, when you look at how the pandemic impacted across the country, you saw more regional differences, whereas kind of post the summer, you saw much more across the U.S. impact. And it all just kind of layers on top of each other. And, you know, as I mentioned, I mean, the Erixia prescriptions grew across the year because I think that the messaging that we're delivering is having an impact. But the overall market is shrinking. So it may have been kind of muted a little bit in what we were seeing. But clearly, as we go into the fourth quarter, as I said, we still grew in the fourth quarter, just not to the extent that we had expected. And then when you look at the caution that we're hearing from the people who are treating these patients, I think it just behooves us to reflect that caution to you as well.

Okay. Understood. Thanks, John. Thanks, Ed.

Thank you. And our next question comes from David Leibowitz with Morgan Stanley. Your line is open.

Thank you for taking the question. When you think about Eurexia going into the first quarter, do you expect to see similar disruption with respect to the IDA, I guess, re-approval, so to speak? Reauthorizations. Reauthorizations.

Yeah, certainly. I mean, that's an annual event for us at this point to ensure that all of the patients who are on have a reauthorization. The team did a great job with that last year. I think similarly they're doing that this year, but it's still an impact. There's no question. I mean, I think when we look at 20 versus 19, you saw a much less stark difference. But, you know, what's really the challenge here is to layer on what's COVID, how is COVID going to impact this as well? You know, are we seeing softness because of, you know, through authorizations, we'll get those done and climb, or is it, you know, we're actually losing patients from the market? And, you know, that's what we have to work on. And it really is just to say, That Q1 is always soft, but be cautious about, you know, kind of how COVID is going to impact us.

Thank you for that. And on R&D, clearly the numbers are stepping down as the Phase 2 program is done. Should we look at or view as the run rate, or will it continue to step down as we move into next year?

Yeah, so we're not providing specific guidance on the ramp, but I think what I would just give context is while the Phase 3s do continue to wind down from an expense perspective, we are investing in the supply chain build for Vatadustat globally before its approval, so we can't capitalize any of the inventory yet. It will run through the R&D expense line.

Okay. Okay.

And we do have the other studies like Modify and Focus, the three times weekly study. So there's still a significant rate of R&D. Certainly not like we had with Innovate and Protect. Sure.

Makes sense. And then I guess my last question on milestones. I know originally We had anticipated milestones in 2021. How should we think about milestones of payments relative to the submission and approval for Vata-Dustat now in the context of how things have shifted?

Yes, so I would say I don't think anything has shifted. We're still on track, and we've just provided the guidance on, you know, submitting the NDA by mid-second quarter. The milestones themselves are due to us upon approval in the U.S. and Europe and tied to the DD and NDD indications.

So that would likely be 2022. Is it based on, is the $250 million, is it half for each indication, so $125 per indication, or is it just $250 collectively for an approval overall?

So we can... We haven't really disclosed what each of the individual milestones are and what their breakouts are, but you can assume that there are various milestones that are attached to USDD, USNDD, XUS, et cetera.

For OTSUCA.

For OTSUCA, yes. Sorry.

Okay. Thank you for that.

Thanks.

Thanks, David.

Thank you. As a reminder, ladies and gentlemen, that's star one to ask your question. Our next question comes from Eric Joseph with JP Morgan. Your line is open.

Good morning. Thanks for taking the questions. First, we'd be curious to get your thoughts on how conducive the current COVID environment is for new product launches and HIPP uptake and whether COVID is a net positive or negative in your view for Rooks Atastat, assuming it's first to market with its approval, potential approval later this quarter. And then just following up on your comments on home dialysis, how high do you see, do you ultimately see that trending as a proportion of overall dialysis patients? And, you know, how should we be thinking about the splitting up of the commercial and detailing effort between you of SUCA and V4 in that patient population? Thanks.

Sure. So I won't comment on another product's launch. Obviously, COVID has impacted everything about how we do, and Chris mentioned the more challenging access for our reps. As we think about it, that's something we're working to get around. I'm sure other companies in the space are all working to try to get to physicians. you know, it is clear when we think about our access to physicians and dialysis, with the kind of impact you're having for COVID and dialysis patients, physicians are really focused on keeping their patients alive and getting them vaccinated. And, you know, as I think about Erixia, I've been really pleased with the growth that we've seen given that focus hasn't been on changing care or doing new things. It's been on you know, just kind of keeping folks in the chair and healthy and alive. So, you know, I think that's just a backdrop that, you know, until our population is fully vaccinated is going to be a challenge for them. And, you know, as I mentioned on the home dialysis side, it's, you know, there were some very aggressive goals that were set out during the Trump administration when, you know, when they had this focus on American focus on kidney health, that were kind of looking for at least a quarter of new patients to be on home dialysis, I can't remember exactly when, within a few years. That was pretty aggressive. It does take more to get a patient on home dialysis than it does on in-center dialysis, patients want it, the government wants it, and dialysis providers want to provide it. And to remain competitive, they'll have to move in that direction. So, you know, they're all looking at how they can grow their home programs. Exactly where that lands, you know, obviously I'm not sure, but, you know, it is, as I said, it's sub-20% of the market today. You know, that will grow significantly because it's growing quickly. And, you know, you know, we'll see together. But that's going to be very important. And when we have conversations with physicians, this is the – that's the kind of market that they just get extremely excited about having a once-a-day oral product to deliver to patients. And not in a small way, that's also – Arixia is also an important product in the home market as well. So we've got a lot of traction there as well.

Okay, great. And maybe just a follow-up question. you said on, um, with respect to three times weekly, uh, and having data on that administration profile at launch, can you just kind of clarify what, um, studies you are referring to there and whether we should anticipate, um, results from the forward to, uh, trial, which completed, and there's a, you know, fairly decently sized trial, um, ahead of, uh, ahead of, um, a launch, approval and launch decision. I'm going to do that, thanks.

Yeah, FOR2 was a small trial that was, you know, kind of really asking a lot of different questions. We have that data. We'll be presenting that at a scientific meeting. The studies that really are going to underpin the three times weekly supplemental NDA are the Modify study, which our partner Otsuka is running in the U.S. and in Europe, and Focus, which we're running here in the U.S., and both of those studies are ongoing, and as I said, we do expect to have data from them both by the time we launch Vata-Dustat in the U.S., and obviously we'll report that data and then use it to quickly file a supplemental NDA for that dosing regimen.

Okay, got it. Thanks for the call. I appreciate you taking the question. Thanks, Eric.

Thank you. And currently I'm showing no further questions. At this time, I'd like to turn the call back over to Mr. John Butler for closing comments.

Thank you, Norma, and thanks, everyone, for joining us this morning. We look forward to updating you on what will be an exciting 2021 for Akiva. Thank you all for joining.

Ladies and gentlemen this concludes today's conference call. Thank you for your participation. You may now disconnect. Everyone have a wonderful day.